ImmunoGen, Inc. (NASDAQ:IMGN) Receives $6.61 Average Price Target from Analysts

ImmunoGen, Inc. (NASDAQ:IMGN) has been given a consensus recommendation of “Hold” by the eleven research firms that are covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and six have given a buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $7.72.

A number of equities research analysts recently issued reports on IMGN shares. Jefferies Group LLC reissued a “buy” rating and set a $6.00 price target on shares of ImmunoGen in a research note on Wednesday, April 12th. Canaccord Genuity set a $6.00 price target on ImmunoGen and gave the stock a “buy” rating in a research note on Saturday, May 6th. Zacks Investment Research raised ImmunoGen from a “hold” rating to a “buy” rating and set a $7.75 price target for the company in a research note on Tuesday, June 27th. BidaskClub downgraded ImmunoGen from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 19th. Finally, Cantor Fitzgerald set a $5.00 price objective on ImmunoGen and gave the stock a “hold” rating in a report on Sunday, June 4th.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by BBNS and is the sole property of of BBNS. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://baseballnewssource.com/markets/immunogen-inc-nasdaqimgn-receives-6-61-average-target-price-from-analysts-updated-updated/1249996.html.

ImmunoGen (IMGN) remained flat at $5.82 during trading on Tuesday. 2,064,246 shares of the company’s stock traded hands. The company has a 50-day moving average price of $6.34 and a 200 day moving average price of $4.30. ImmunoGen has a 52 week low of $1.51 and a 52 week high of $8.04. The stock’s market capitalization is $507.35 million.

ImmunoGen (NASDAQ:IMGN) last posted its quarterly earnings data on Friday, July 28th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.07. The company had revenue of $39.02 million during the quarter, compared to the consensus estimate of $30.59 million. During the same period in the previous year, the business earned ($0.53) earnings per share. ImmunoGen’s revenue for the quarter was up 426.6% on a year-over-year basis. Equities research analysts expect that ImmunoGen will post ($0.84) earnings per share for the current year.

A number of hedge funds have recently modified their holdings of the company. Redmile Group LLC purchased a new stake in ImmunoGen during the first quarter worth $15,421,000. Teachers Advisors LLC increased its stake in ImmunoGen by 10.6% in the fourth quarter. Teachers Advisors LLC now owns 209,859 shares of the biotechnology company’s stock worth $428,000 after buying an additional 20,171 shares during the last quarter. Stephens Inc. AR purchased a new stake in ImmunoGen during the first quarter worth $152,000. KBC Group NV increased its stake in ImmunoGen by 6.4% in the first quarter. KBC Group NV now owns 299,613 shares of the biotechnology company’s stock worth $1,160,000 after buying an additional 17,893 shares during the last quarter. Finally, Janney Montgomery Scott LLC increased its stake in ImmunoGen by 11.1% in the first quarter. Janney Montgomery Scott LLC now owns 58,815 shares of the biotechnology company’s stock worth $228,000 after buying an additional 5,893 shares during the last quarter. 74.38% of the stock is owned by institutional investors.

About ImmunoGen

ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.

Analyst Recommendations for ImmunoGen (NASDAQ:IMGN)

Receive News & Ratings for ImmunoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury
Chicago Cubs Must Survive Without Willson Contreras
Chicago Cubs Must Survive Without Willson Contreras
Cleveland Indians Acquire Jay Bruce From New York Mets
Cleveland Indians Acquire Jay Bruce From New York Mets
Injury to CC Sabathia Adds to Yankees’ Concerns
Injury to CC Sabathia Adds to Yankees’ Concerns
Darren Daulton Former Catcher with Phillies Dies
Darren Daulton Former Catcher with Phillies Dies


Leave a Reply

 
© 2006-2017 BBNS.